RC220 + Doxorubicin (Adriamycin)
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumours
Conditions
Solid Tumours, Advanced Solid Tumours
Trial Timeline
Apr 2, 2025 → Jan 31, 2029
NCT ID
NCT06815575About RC220 + Doxorubicin (Adriamycin)
RC220 + Doxorubicin (Adriamycin) is a phase 1 stage product being developed by Race Oncology for Solid Tumours. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06815575. Target conditions include Solid Tumours, Advanced Solid Tumours.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06815575 | Phase 1 | Recruiting |
Competing Products
20 competing products in Solid Tumours